This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Efficacy of Bronchitol in Bronchiectasis

This study has been completed.
Information provided by:
Pharmaxis Identifier:
First received: January 13, 2006
Last updated: August 27, 2008
Last verified: August 2008
Study will assess the safety and effectiveness of 12 week treatment with the study medication, Bronchitol, in subjects with bronchiectasis (a lung disease where patients have trapped, and often infected, thick, sticky mucus). Past studies have shown Bronchitol inhalation may help to facilitate the clearance of mucus by altering its rheology (making it less thick and sticky), thereby enhancing the shift of stagnant mucus from the lungs. On completion of the double blind phase, subjects will have the opportunity to participate in a 52 week open label phase.

Condition Intervention Phase
Bronchiectasis Drug: Mannitol Drug: placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III Multicenter, Randomised, Parallel, Placebo-Controlled, Double-Blind Study to Investigate the Safety and Efficacy of Treatment With Bronchitol (Dry Powder Mannitol) in the Symptomatic Treatment of Bronchiectasis.

Resource links provided by NLM:

Further study details as provided by Pharmaxis:

Primary Outcome Measures:
  • 24 hour sputum clearance [ Time Frame: 24 hours / 12 weeks ]
  • Quality of Life SGRQ [ Time Frame: 12 weeks ]

Secondary Outcome Measures:
  • bronchiectasis symptoms [ Time Frame: 12 weeks ]
  • cough severity [ Time Frame: 12 weeks ]
  • exercise capacity [ Time Frame: 12 weeks ]
  • lung function, including gas transfer [ Time Frame: 12 weeks ]
  • antibiotic use [ Time Frame: 12 weeks ]
  • bronchial wall thickening and inflammation [ Time Frame: 12 weeks ]
  • adverse events [ Time Frame: 12 weeks / 12 months ]
  • haematology, biochemistry, [ Time Frame: 12 weeks / 12 months ]
  • sputum microbiology quantitative and qualitative [ Time Frame: 12 weeks / 12 months ]

Estimated Enrollment: 354
Study Start Date: March 2006
Study Completion Date: July 2008
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: Mannitol
320mg BD 12 weeks followed by 40 weeks open label
2 Drug: placebo
BD for 12 weeks


Ages Eligible for Study:   15 Years to 80 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Non cystic fibrosis bronchiectasis
  • Have FEV1 50% - 80% predicted and ≥1.0L
  • Have chronic sputum production of >10 mL per day on the majority of days in the 3 months prior to study entry

Exclusion Criteria:

  • Be using hypertonic saline or mucolytic pharmacological agents concurrently or in the 4 weeks prior to study entry
  • Have airway hyperresponsiveness as defined by a positive Aridol challenge
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00277537

Australia, Australian Capital Territory
Canberra Hospital
Canberra, Australian Capital Territory, Australia
Australia, New South Wales
Royal Prince Alfred Hospital
Camperdown Sydney, New South Wales, Australia
St George Hospital
Kogarah, New South Wales, Australia
John Hunter Hospital
Newcastle, New South Wales, Australia
Royal North Shore Hospital
St Leonards, New South Wales, Australia
Bankstown Hospital
Sydney, New South Wales, Australia
Australia, Queensland
Mater Adult Hospital
Brisbane, Queensland, Australia
Cairns Base Hospital
Cairns, Queensland, Australia
Australia, South Australia
Repatriation General Hospital
Adelaide, South Australia, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Burnside War Memorial Hospital
Toorak Gardens, Adelaide, South Australia, Australia
Australia, Victoria
Peninsula Health Frankston Hospital
Frankston, Victoria, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Australia, Western Australia
AARI Sir Charles Gairdner Hospital
Perth, Western Australia, Australia
Royal Perth Hospital
Perth, Western Australia, Australia
New Zealand
Greenlane Hospital
Auckland, New Zealand
Middlemore Hospital
Auckland, New Zealand
United Kingdom
Belfast City Hospital
Belfast, Northern Ireland, United Kingdom
Papworth Hospital
Cambridge, United Kingdom
Glenfield Hospital
Leicester, United Kingdom
North West Lung Centre, Wythshawe Hospital
Manchester, United Kingdom
Norfolk and Norwich University Hospital
Norwich, United Kingdom
Sponsors and Collaborators
Study Director: Brett Charlton Pharmaxis Ltd Australia
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Dr Brett Charlton, Pharmaxis Ltd Identifier: NCT00277537     History of Changes
Other Study ID Numbers: DPM-B-301
Study First Received: January 13, 2006
Last Updated: August 27, 2008

Keywords provided by Pharmaxis:

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Diuretics, Osmotic
Natriuretic Agents
Physiological Effects of Drugs processed this record on September 25, 2017